AI assistant
Sending…
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2017
Jun 14, 2017
30583_dirs_2017-06-13_fea615b5-6bd5-45f5-9368-e05ab6393fb9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2017-06-09
Reporting Person: Davis George Eric (EVP, General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-06-09 | Common Stock | M | 5464 | $21.51 | Acquired | 79806 | Direct |
| 2017-06-09 | Common Stock | M | 3775 | $26.49 | Acquired | 83581 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-09 | Stock Option (Right to buy Common Stock) | $21.51 | M | 5464 | Disposed | 2020-05-11 | Common Stock (5464) | Direct |
| 2017-06-09 | Stock Option (Right to buy Common Stock) | $26.49 | M | 3775 | Disposed | 2021-05-11 | Common Stock (3775) | Direct |
Footnotes
F1: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
More from BIOMARIN PHARMACEUTICAL INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Interim / Quarterly Report
2026
May 5
Report Publication Announcement
2026
May 4
M&A Activity
2026
Apr 27
M&A Activity
2026
Apr 23
Annual Report
2026
Apr 21
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19